DePuy Synthes Companies Enhances Adult Deformity Offering With Four New Products And A New Education Solution

LAS VEGASMarch 26, 2015 /PRNewswire/ — DePuy Synthes Companies announced the addition of four new products to its adult deformity portfolio as well as a new education offering, continuing its expansion of one of the broadest spine portfolios in the industry. The products were displayed by DePuy Synthes Spine* at the 81st annual meeting of the American Academy of Orthopaedic Surgeons (AAOS).

The products include the EXPEDIUM® Osteotomy System for use during spinal reconstruction and VIPER® Cortical Fix X-Tabs for enhanced fixation in percutaneous surgery. The company also recently added VIVIGEN® Cellular Bone Matrix** for the repair or reconstruction of musculoskeletal defects and enhancements to the SYNAPSE™ System of implants and instruments designed to provide more surgical options and the flexibility required to accommodate variations in patient anatomy during posterior stabilization of the upper spine.

About the New Products

  • EXPEDIUM® Osteotomy System is a comprehensive instrument set for facilitating procedures during the most complex portion of deformity correction. The new instruments address osteotomies from a Ponte procedure to a vertebral column resection.
  • The VIPER® Cortical Fix X-Tab design offers minimal muscle trauma and built in reduction through a streamlined technique.  Furthermore, the Cortical Fix thread form doubles the number of contact points within the pedicle and increases pull out resistance for enhanced fixation***.
  • The SYNAPSE System uses 3.5 mm and 4.0 mm titanium alloy rods. When combined with the Occipital Cervical Fusion System and the Universal Spinal System or EXPEDIUM Spinal System, constructs can extend from the occiput to the lower spine.  The company recently received clearance from the U.S. Food and Drug Administration (FDA) to market its SYNAPSETM Occipital-Cervical-Thoracic (OCT) System with posterior cervical screws, the first time cervical screws have been indicated for use with a screw-rod posterior fixation system.
  • VIVIGEN® Cellular Bone Matrix provides a viable alternative to autograft that delivers all the properties required for bone formation. VIVIGEN, an HCT/P (Human Cells, Tissues, and Cellular and Tissue-based Product), is comprised of cryopreserved viable, lineage committed bone cells within a cortical cancellous bone matrix and demineralized bone. DePuy Synthes Spine* and DePuy Synthes Biomaterials* have an exclusive worldwide agreement to market and promote VIVIGEN, which was developed by LifeNet Health, a world leader in allograft bio-implants and cellular therapies.


Josh Sandberg

Josh Sandberg is the President and CEO of Ortho Spine Partners and sits on several company and industry related Boards. He also is the Creator and Editor of OrthoSpineNews.

Related Articles

Back to top button